| Alexander James Long, MD | |
|
1625 E 4th St, Los Angeles, CA 90033-4201 | |
| (323) 268-8391 | |
| Not Available |
| Full Name | Alexander James Long |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 1625 E 4th St, Los Angeles, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205213980 | NPI | - | NPPES |
| Q033383 | Medicaid | TN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventist Health Hanford | Hanford, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cep America - California | 6103739131 | 954 |
News Archive
SCIENTISTS at the University of Huddersfield are pioneering the use of a special gel that is ideal for administering medication to young children and others - including the elderly - who have difficulty swallowing pills and capsules. Unlike purely liquid medicines, the gel delays the release of the drug, so that it has maximum effect.
Thirty thousand Americans suffer severe neurological damage or death from brain aneurysms each year and the existing treatments eventually fail in nearly half of patients. Currently, these "bubbles" in the blood vessel are either clamped off, which requires invasive brain surgery, or filled with platinum coils to induce clotting in the aneurysm. Both treatments, although somewhat effective, can have subsequent problems, including inflammation, incomplete healing, and the development of secondary aneurysms adjacent to the initial site. These complications result in approximately 40 percent of patients needing additional treatment to attempt to re-repair the aneurysm.
Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG). The study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and, together with results from additional upcoming studies, will support its regulatory filing in Europe and the US.
WellCare Health Plans, Inc. today reported results for the third quarter and nine months ended September 30, 2009. As determined under generally accepted accounting principles ("GAAP"), the Company reported net income of $28.7 million, or $0.68 per diluted share, for the third quarter 2009, compared with a net loss of $18.2 million, or $0.44 per diluted share, for the third quarter 2008.
› Verified 4 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
SCIENTISTS at the University of Huddersfield are pioneering the use of a special gel that is ideal for administering medication to young children and others - including the elderly - who have difficulty swallowing pills and capsules. Unlike purely liquid medicines, the gel delays the release of the drug, so that it has maximum effect.
Thirty thousand Americans suffer severe neurological damage or death from brain aneurysms each year and the existing treatments eventually fail in nearly half of patients. Currently, these "bubbles" in the blood vessel are either clamped off, which requires invasive brain surgery, or filled with platinum coils to induce clotting in the aneurysm. Both treatments, although somewhat effective, can have subsequent problems, including inflammation, incomplete healing, and the development of secondary aneurysms adjacent to the initial site. These complications result in approximately 40 percent of patients needing additional treatment to attempt to re-repair the aneurysm.
Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG). The study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and, together with results from additional upcoming studies, will support its regulatory filing in Europe and the US.
WellCare Health Plans, Inc. today reported results for the third quarter and nine months ended September 30, 2009. As determined under generally accepted accounting principles ("GAAP"), the Company reported net income of $28.7 million, or $0.68 per diluted share, for the third quarter 2009, compared with a net loss of $18.2 million, or $0.44 per diluted share, for the third quarter 2008.
› Verified 4 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548667843 PECOS PAC ID: 6103739131 Enrollment ID: O20040121000458 |
News Archive
SCIENTISTS at the University of Huddersfield are pioneering the use of a special gel that is ideal for administering medication to young children and others - including the elderly - who have difficulty swallowing pills and capsules. Unlike purely liquid medicines, the gel delays the release of the drug, so that it has maximum effect.
Thirty thousand Americans suffer severe neurological damage or death from brain aneurysms each year and the existing treatments eventually fail in nearly half of patients. Currently, these "bubbles" in the blood vessel are either clamped off, which requires invasive brain surgery, or filled with platinum coils to induce clotting in the aneurysm. Both treatments, although somewhat effective, can have subsequent problems, including inflammation, incomplete healing, and the development of secondary aneurysms adjacent to the initial site. These complications result in approximately 40 percent of patients needing additional treatment to attempt to re-repair the aneurysm.
Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG). The study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and, together with results from additional upcoming studies, will support its regulatory filing in Europe and the US.
WellCare Health Plans, Inc. today reported results for the third quarter and nine months ended September 30, 2009. As determined under generally accepted accounting principles ("GAAP"), the Company reported net income of $28.7 million, or $0.68 per diluted share, for the third quarter 2009, compared with a net loss of $18.2 million, or $0.44 per diluted share, for the third quarter 2008.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alexander James Long, MD 7131 E Gage Ave Apt 102, Commerce, CA 90040-3862 Ph: (626) 833-2156 | Alexander James Long, MD 1625 E 4th St, Los Angeles, CA 90033-4201 Ph: (323) 268-8391 |
News Archive
SCIENTISTS at the University of Huddersfield are pioneering the use of a special gel that is ideal for administering medication to young children and others - including the elderly - who have difficulty swallowing pills and capsules. Unlike purely liquid medicines, the gel delays the release of the drug, so that it has maximum effect.
Thirty thousand Americans suffer severe neurological damage or death from brain aneurysms each year and the existing treatments eventually fail in nearly half of patients. Currently, these "bubbles" in the blood vessel are either clamped off, which requires invasive brain surgery, or filled with platinum coils to induce clotting in the aneurysm. Both treatments, although somewhat effective, can have subsequent problems, including inflammation, incomplete healing, and the development of secondary aneurysms adjacent to the initial site. These complications result in approximately 40 percent of patients needing additional treatment to attempt to re-repair the aneurysm.
Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG). The study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and, together with results from additional upcoming studies, will support its regulatory filing in Europe and the US.
WellCare Health Plans, Inc. today reported results for the third quarter and nine months ended September 30, 2009. As determined under generally accepted accounting principles ("GAAP"), the Company reported net income of $28.7 million, or $0.68 per diluted share, for the third quarter 2009, compared with a net loss of $18.2 million, or $0.44 per diluted share, for the third quarter 2008.
› Verified 4 days ago
Srpouhi Gasparyan, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4950 W Sunset Blvd Fl 4, Los Angeles, CA 90027 Phone: 626-318-8104 | |
Dr. Olympia Alexandra Kabobel, D.O. M.P.H Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1520 San Pablo St Ste 1300, Los Angeles, CA 90033 Phone: 323-442-5900 | |
Joy Go Legaspi, NP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 757 Westwood Plz Ste 8638, Los Angeles, CA 90095 Phone: 310-267-7834 | |
Dr. Afshin Akhavan, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 530 E Washington Blvd, Los Angeles, CA 90015 Phone: 213-747-2626 Fax: 213-749-7500 | |
Bruno J. Lewin, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4733 W Sunset Blvd, Los Angeles, CA 90027 Phone: 323-783-4011 | |
Gabriel Sanchez-aldana Jr., M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1414 S Grand Ave Ste 200, Los Angeles, CA 90015 Phone: 213-419-9600 Fax: 213-419-9900 | |
Dr. Santiago Dayoan Corpuz, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 4643 Beverly Blvd Ste 101, Los Angeles, CA 90004 Phone: 323-461-4183 Fax: 323-461-0864 |